mk0773
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2005 (NCT01011725)
Timeline
Indications
Mechanism of action
- Androgen ReceptorMODULATOR
AR modulator
SARM
Chemistry & pharmacology
Loading structure…
SMILES
CN1C(=O)C(F)=C[C@]2(C)[C@H]3CC[C@]4(C)[C@@H](C(=O)NCc5nc6cccnc6[nH]5)CC[C@H]4[C@@H]3CC[C@@H]12- Mol. weight
- 479.6 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545333 ↗
- ChEMBLCHEMBL3221237 ↗
Also known as
- 3-fluoro-n-(3h-imidazo(4,5-b)pyridin-2-ylmethyl)-1,4a,6a-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1h-indeno(5,4-f)quinoline-7-carboxamide
- mk0773
- mk0773
- mk0773
- mk 0773
- mk-0773
- mk-0773
- mk-0773
- mk-0773
- pf-05314882
- pf-05314882
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00529659 | Phase 2 | Oct 1, 2007 | Merck |
| NCT01017458 | Phase 1 | Jun 1, 2007 | Merck |
| NCT01011725 | Phase 1 | Nov 1, 2005 | Merck |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 3 | 3 | 2 | 2005 |
1 organizations
Page 1 / 1